Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$227.00
-1.0%		$246.29
$186.05
▼
$282.15
$14.30B0.38988,599 shs667,445 shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$59.82
-0.1%		$56.36
$33.76
▼
$61.66
$14.83B0.472.21 million shs3.13 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$17.13
-2.6%		$15.64
$12.07
▼
$29.23
$14.07B-1.517.61 million shs4.37 million shs
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$52.02
-0.2%		$62.15
$22.59
▼
$68.73
$4.91B1.131.94 million shs1.42 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%+0.60%-13.01%-13.57%+9.39%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%+2.52%+6.66%+6.82%+56.91%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
0.00%+5.01%+0.23%+14.97%-17.61%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
0.00%-8.43%-21.22%-7.39%+107.19%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$227.00
-1.0%		$246.29
$186.05
▼
$282.15
$14.30B0.38988,599 shs667,445 shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$59.82
-0.1%		$56.36
$33.76
▼
$61.66
$14.83B0.472.21 million shs3.13 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$17.13
-2.6%		$15.64
$12.07
▼
$29.23
$14.07B-1.517.61 million shs4.37 million shs
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$52.02
-0.2%		$62.15
$22.59
▼
$68.73
$4.91B1.131.94 million shs1.42 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%+0.60%-13.01%-13.57%+9.39%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%+2.52%+6.66%+6.82%+56.91%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
0.00%+5.01%+0.23%+14.97%-17.61%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
0.00%-8.43%-21.22%-7.39%+107.19%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$313.2137.98% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.35
Hold$50.79-15.10% Downside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.53
Moderate Buy$28.6167.00% Upside
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.75
Moderate Buy$69.5033.60% Upside

Current Analyst Ratings Breakdown

Latest TVTX, EXEL, ASND, and SMMT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/9/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetSector Perform$51.00
10/8/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (A-) ➝ Buy (A)
10/8/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetSector Perform$46.00 ➝ $45.00
10/7/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$52.00 ➝ $54.00
10/5/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
10/1/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$18.00 ➝ $20.00
9/30/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/29/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuy$41.00
9/29/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform
9/29/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$30.00
9/25/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$40.00 ➝ $43.00
(Data available from 10/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M17.38N/AN/A($2.97) per share-76.43
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.44B6.08$3.03 per share19.77$8.06 per share7.42
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/A$0.85 per shareN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$591.33M8.29$0.36 per share143.94$1.28 per share40.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8917.6125.36N/A70.99%32.54%7.71%11/11/2026 (Estimated)
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.1818.8116.121.7835.33%42.17%31.76%11/3/2026 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$1.08B-$1.12N/AN/AN/AN/A-168.94%-141.92%10/19/2026 (Estimated)
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$25.55M-$0.46N/A19.78N/A-7.35%-55.15%-6.88%10/29/2026 (Estimated)

Latest TVTX, EXEL, ASND, and SMMT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/3/2026Q3 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8780N/AN/AN/A$646.95 millionN/A
10/29/2026Q3 2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$0.0299N/AN/AN/A$195.68 millionN/A
10/19/2026Q3 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.2871N/AN/AN/A$0.07 millionN/A
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/5/2026Q2 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8530$0.91+$0.0570$0.8438$636.40 million$628.69 million
8/4/2026Q2 2026
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$0.1347-$0.10+$0.0347-$0.37$157.27 million$169.58 million
7/23/2026Q2 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.2744-$0.28-$0.0056-$0.28$0.11 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.46
3.38
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
6.96
6.96
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
24.58
4.05
3.99

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
83.50%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
4.44%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077247.78 million241.34 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
265799.73 million131.96 millionOptionable
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
49794.26 million90.08 millionOptionable

Recent News About These Companies

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 12 at 5:00 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20261012301172/en/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4/
Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock Has Consensus Price Target of $69.50
October 11 at 2:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31107108
Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock Has Consensus Target Price of $69.50
October 11 at 2:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-travere-therapeutics-inc-nasdaq-tvtx-stock-has-consensus-target-price-of-6950-2026-10-11/
Insight Wealth Strategies LLC Makes New Investment in Travere Therapeutics, Inc. $TVTX
October 9 at 1:11 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-insight-wealth-strategies-llc-makes-new-investment-in-travere-therapeutics-inc-tvtx-2026-10-09/
Travere to Present New Data Supporting FILSPARI as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
October 6, 2026  |  marketscreener.comM
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
September 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-travere-therapeutics-inc-to-contact-law-firm-302893828.html
Travere Therapeutics (TVTX) Sets CEO Handover For December 2026
September 22, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/travere-therapeutics-tvtx-sets-ceo-011323451.html
Travere Therapeutics (TVTX) Stock May Trade Above Fair Value Today
September 22, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/travere-therapeutics-tvtx-stock-may-141323925.html
Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down - Here's Why
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-travere-therapeutics-nasdaq-tvtx-shares-gap-down-heres-why-2026-09-22/
Travere Therapeutics' (TVTX) "Outperform" Rating Reaffirmed at Wedbush
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-travere-therapeutics-tvtx-outperform-rating-reaffirmed-at-wedbush-2026-09-22/
Travere Therapeutics' (TVTX) Buy Rating Reaffirmed at HC Wainwright
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-travere-therapeutics-tvtx-buy-rating-reaffirmed-at-hc-wainwright-2026-09-22/
Travere Therapeutics, Inc. Announces CEO Changes, Effective December 1, 2026
September 21, 2026  |  marketscreener.comM
Travere Therapeutics Announces Planned Chief Executive Officer Transition
September 21, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260921057187/en/travere-therapeutics-announces-planned-chief-executive-officer-transition/
Travere Therapeutics Insider Sold Shares Worth $2,785,021, According to a Recent SEC Filing
September 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/travere-therapeutics-insider-sold-shares-074625088.html
Travere Therapeutics (NASDAQ:TVTX) CAO Sandra Calvin Sells 5,375 Shares
September 18, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-tvtx-insider-buying-and-selling-2026-09-18/
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CAO Sells $335,023.75 in Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-travere-therapeutics-nasdaq-tvtx-cao-sells-33502375-in-stock-2026-09-17/
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) EVP Sells $538,909.74 in Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-travere-therapeutics-nasdaq-tvtx-evp-sells-53890974-in-stock-2026-09-17/
Elizabeth Reed Sells 37,500 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-elizabeth-reed-sells-37500-shares-of-travere-therapeutics-nasdaq-tvtx-stock-2026-09-17/
Jula Inrig Sells 44,674 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-jula-inrig-sells-44674-shares-of-travere-therapeutics-nasdaq-tvtx-stock-2026-09-17/
Travere Therapeutics (NASDAQ:TVTX) CFO Sells $3,148,668.72 in Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-travere-therapeutics-nasdaq-tvtx-cfo-sells-314866872-in-stock-2026-09-17/
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CEO Sells $5,956,165.16 in Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-travere-therapeutics-nasdaq-tvtx-ceo-sells-595616516-in-stock-2026-09-17/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$227.00 -2.23 (-0.97%)
Closing price 04:00 PM Eastern
Extended Trading
$227.02 +0.03 (+0.01%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$59.82 -0.04 (-0.07%)
Closing price 04:00 PM Eastern
Extended Trading
$60.58 +0.76 (+1.26%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$17.13 -0.46 (-2.62%)
Closing price 04:00 PM Eastern
Extended Trading
$17.12 0.00 (-0.03%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Travere Therapeutics stock logo

Travere Therapeutics NASDAQ:TVTX

$52.02 -0.11 (-0.21%)
Closing price 04:00 PM Eastern
Extended Trading
$52.01 -0.01 (-0.02%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas